InspireMD Inc (NYSEAMERICAN:NSPR)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $0.59, but opened at $0.69. InspireMD shares last traded at $0.56, with a volume of 532,641 shares trading hands.
NSPR has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of InspireMD in a research note on Wednesday, May 13th. Zacks Investment Research raised shares of InspireMD from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Tuesday.
InspireMD (NYSEAMERICAN:NSPR) last posted its quarterly earnings results on Tuesday, May 12th. The medical equipment provider reported ($0.43) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.20. The firm had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.00 million.
A hedge fund recently raised its stake in InspireMD stock. Barclays PLC lifted its holdings in InspireMD Inc (NYSEAMERICAN:NSPR) by 51.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,475 shares of the medical equipment provider’s stock after buying an additional 9,697 shares during the quarter. Barclays PLC owned approximately 0.78% of InspireMD worth $31,000 as of its most recent SEC filing.
About InspireMD (NYSEAMERICAN:NSPR)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.
Featured Story: Equity Income
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.